ARTICLE | Clinical News
SYI-2074: Phase II started
December 22, 2008 8:00 AM UTC
Synvista began a double-blind, placebo-controlled, Israeli Phase II trial of topical SYI-2074 in 30 patients. Synvista has exclusive rights to SYI-2074 from Oxis. Novel Therapeutic developed the topic...